عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

France’s César Awards Honors Two Tunisians Women

Canadian-Tunisian Filmmaker Monia Chokri won the César Award for Best Foreign Film, for her feature ‘Simple comme Sylvain’. (AP)
Canadian-Tunisian Filmmaker Monia Chokri won the César Award for Best Foreign Film, for her feature ‘Simple comme Sylvain’. (AP)
TT
TT

France’s César Awards Honors Two Tunisians Women

Canadian-Tunisian Filmmaker Monia Chokri won the César Award for Best Foreign Film, for her feature ‘Simple comme Sylvain’. (AP)
Canadian-Tunisian Filmmaker Monia Chokri won the César Award for Best Foreign Film, for her feature ‘Simple comme Sylvain’. (AP)

The prestigious Olympia of Paris hosted the 45th edition of the César Awards, which honors achievers in all the sectors of the French cinema, on Friday, February 24. Among tens of international celebrities, the accomplishments of two Arab women were celebrated at the highly-anticipated European event.

Kaouther Ben Hania won the Best Documentary Award for her documentary "Four Daughters" (Les Filles d’Olfa). The work was screened in several festivals and was nominated for the Oscars.

Born in Sidi Bouzid, in 1977, the Tunisian filmmaker studied at the School of Art and Cinema in Tunisia, has several documentaries, took part in a feature film writing workshop funded by Euromed, and collaborated with Al Jazeera Documentary. Kaouther Ben Hania took advantage of her Olympia appearance to raise her voice and angrily call for stopping the children killing in Gaza. “What’s happening there is so horrible. No one can say, ‘I didn’t know.’ This is the first massacre on live stream, live on our telephones,” she said in her speech.

Also, Quebecois-Tunisian Filmmaker Monia Chokri won the César Award for Best Foreign Film, for her feature ‘Simple comme Sylvain’. It tells the story of Sophie, a university professor who lived a peaceful life with her husband, Xavier, until she met Sylvain, the maintenance worker who came to restore their summer house.

Monia was born in Québec, in 1982, to two leftist parents. She studied acting at the Conservatoire d'art dramatique de Montréal. She played many roles in cinema and theater, before directing her first award-winning short film "An Extraordinary Person" in 2013. In 2019, she won the "Un Certain Regard Jury's Coup de Cœur Award" at the Cannes Film Festival.

This year, the participants at the César Awards raised their voice to denounce the silence in face of the sexual harassment that young actresses, filmmakers and producers have been subjected to in the industry. French director Justine Triet's "Anatomy of A Fall" won six trophies, including the Best Film Award at the César festival. The film has already received Cannes’ Palme D’Or last year and has been nominated for the forthcoming edition of the Oscars.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”